[go: up one dir, main page]

MX2016003327A - Composicion farmaceutica de citrato de sildenafilo en forma de suspension para uso oral. - Google Patents

Composicion farmaceutica de citrato de sildenafilo en forma de suspension para uso oral.

Info

Publication number
MX2016003327A
MX2016003327A MX2016003327A MX2016003327A MX2016003327A MX 2016003327 A MX2016003327 A MX 2016003327A MX 2016003327 A MX2016003327 A MX 2016003327A MX 2016003327 A MX2016003327 A MX 2016003327A MX 2016003327 A MX2016003327 A MX 2016003327A
Authority
MX
Mexico
Prior art keywords
suspension
sildenafil citrate
pharmaceutical composition
oral use
administration
Prior art date
Application number
MX2016003327A
Other languages
English (en)
Other versions
MX369760B (es
Inventor
Martinez-Alzamora Fernando
Gomez Calvo Antonia
Rizo Martinez Miguel
Sanz Menendez Nuria
Original Assignee
Farmalider Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider Sa filed Critical Farmalider Sa
Publication of MX2016003327A publication Critical patent/MX2016003327A/es
Publication of MX369760B publication Critical patent/MX369760B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral que comprende agua como vehículo y goma xantana e hipromelosa como agentes suspensores, que presenta una gran estabilidad y permite un eficaz enmascaramiento del sabor amargo del principio activo. También se refiere a un procedimiento para la preparación de dicha suspensión y a un envase que la contiene y que está provisto de un dispositivo dosificador para su administración. Esta composición de citrato de sildenafilo en forma de suspensión es adecuada para su administración por vía oral para el tratamiento de la disfunción sexual masculina.
MX2016003327A 2015-03-24 2016-03-14 Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral. MX369760B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201500212A ES2584248B1 (es) 2015-03-24 2015-03-24 Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral

Publications (2)

Publication Number Publication Date
MX2016003327A true MX2016003327A (es) 2017-01-05
MX369760B MX369760B (es) 2019-11-20

Family

ID=55646513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003327A MX369760B (es) 2015-03-24 2016-03-14 Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral.

Country Status (11)

Country Link
US (1) US10016428B2 (es)
EP (1) EP3072515B1 (es)
AU (1) AU2017265087B2 (es)
CY (1) CY1120282T1 (es)
DK (1) DK3072515T3 (es)
ES (2) ES2584248B1 (es)
HR (1) HRP20180819T1 (es)
HU (1) HUE037541T2 (es)
MX (1) MX369760B (es)
PL (1) PL3072515T3 (es)
PT (1) PT3072515T (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006080SA (en) 2017-12-26 2020-07-29 Ftf Pharma Private Ltd Liquid oral formulations for pde v inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
US20070087981A1 (en) * 2002-02-08 2007-04-19 Lavipharm Laboratories, Inc. Water Soluble and Palatable Complexes
US20060024335A1 (en) * 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
JP2011503105A (ja) * 2007-11-12 2011-01-27 ノバルティス アーゲー バルサルタン含有液体組成物
SG192284A1 (en) * 2011-02-11 2013-09-30 Ctc Bio Inc Sildenafil-free base-containing film preparation and method for producing same
ES2475942B1 (es) * 2013-01-11 2015-04-16 Farmalider, S.A. Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa
MX2013001279A (es) * 2013-01-31 2013-08-26 Miguel Angel Garcia Perez Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.

Also Published As

Publication number Publication date
MX369760B (es) 2019-11-20
AU2017265087A1 (en) 2018-01-04
PL3072515T3 (pl) 2018-12-31
HRP20180819T1 (hr) 2018-07-13
CY1120282T1 (el) 2019-07-10
HUE037541T2 (hu) 2018-09-28
ES2584248A1 (es) 2016-09-26
PT3072515T (pt) 2018-05-25
AU2017265087B2 (en) 2018-11-01
US10016428B2 (en) 2018-07-10
EP3072515B1 (en) 2018-02-28
ES2584248B1 (es) 2017-04-19
EP3072515A1 (en) 2016-09-28
US20160279133A1 (en) 2016-09-29
DK3072515T3 (en) 2020-01-06
ES2671543T3 (es) 2018-06-07

Similar Documents

Publication Publication Date Title
MX2021002321A (es) Nuevos metodos.
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
MX2021002322A (es) Nuevos metodos.
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
WO2015120110A3 (en) Novel pharmaceutical formulations
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
NZ714963A (en) Compositions and methods for treating anemia
WO2011156405A3 (en) Oral spray formulations and methods for administration of sildenafil
FI3666258T3 (fi) Menetelmä prader-willin oireyhtymän hoitamiseksi
EP3162804A8 (en) New benzodiazepine derivative and use thereof
AR109093A1 (es) Solución oral que comprende clorhidrato de atomoxetina y sus métodos
MX2020005921A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
MX2016003327A (es) Composicion farmaceutica de citrato de sildenafilo en forma de suspension para uso oral.
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
MY196333A (en) Intranasal Composition Comprising Betahistine
EA201891860A1 (ru) Фармацевтическая композиция пролонгированного высвобождения, содержащая цистеамин или его соли
ZA202200331B (en) Naltrexone formulation
MX2016017315A (es) Formas de dosificacion farmaceutica.
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
GR1008819B (el) Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
UA118656C2 (uk) Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції
MX369548B (es) Gel oral de un inhibidor de la fosfodiesterasa.

Legal Events

Date Code Title Description
FG Grant or registration